<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201012264784N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-06-11</date_registration>
      <primary_sponsor>Tehran University of Medical Siences- Vice-chancellor for reseach</primary_sponsor>
      <public_title>Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after totla hip arthroplasty.</public_title>
      <acronym></acronym>
      <scientific_title>Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after totla hip arthroplasty in sina hospital during 2011-2012.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/5126</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>totla hip arthroplasy.</hc_freetext>
      <i_freetext>Intervention 1: In case group after induction of anesthesia we  infuse 30mg/kg fibrinogen concentrtate IV in 15 minutes.before infusion by means of arterial catheter blood sampling perform and check  it for serum level of fibrinogen in both groups( for baseline).during surgery with 30 minute intervals mean atreial pressure would be registered.blood loss is estimated by means of caclculating number of guazes an longuazes and suction container.each guaze and longuaze consist of 20 and 50 ml respectively.maximum allowable blood loss would be calculated by this equationABL=65 X body weightX(patient Hb - desired Hb for sex an age)/optimal Hb.volume of packed RBC contains about 250 ml RBC which would be diluted with 250 ml warm normal saline and transfused for compensation of blood loss.during surgery with warm crystaloids and warm forced air and thermal monitoring maintaining normothermia.monitoring of acid base  would be performed. Intervention 2: In control(placebo) group after induction of anesthesia we  infuse normal saline in equivalent volume of fibrinogen.before infusion by means of arterial catheter blood sampling perform and check  it for serum level of fibrinogen in both groups( for baseline).during surgery with 30 minute intervals mean atreial pressure would be registered.blood loss is estimated by means of caclculating number of guazes an longuazes and suction container.each guaze and longuaze consist of 20 and 50 ml respectively.maximum allowable blood loss would be calculated by this equationABL=65 X body weightX(patient Hb - desired Hb for sex an age)/optimal Hb.volume of packed RBC contains about 250 ml RBC which would be diluted with 250 ml warm normal saline and transfused for compensation of blood loss.during surgery with warm crystaloids and warm forced air and thermal monitoring maintaining normothermia.monitoring of acid base  would be performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Reza shariat Moharari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>emam khomeini street-sina hospital</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>moharari@sina.tums.ac.ir</email>
        <affiliation>sina hospital-tehran university of medical sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Atabak Nadjafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>emam khomeini street- sina hospital</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>nadjafia@tums.ac.ir</email>
        <affiliation>associated professor-department of anesthesia and critical care-sina hospital TUMS</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
1- patients aged 35-75 years old scheduled for total hip arthroplasty&#13;
2-ASA physical status I and II&#13;
3-hemoglubin level more than 10&#13;
4-MET more than 4&#13;
5-completely fill and sign the informed consent.                   &#13;
Exclusion criteria:&#13;
1-ASA class more than 3&#13;
2-MET&lt;4&#13;
3-pregnancy&#13;
4-history of allergic reaction to blood products specially fibrinogen concentrate&#13;
5-history of DVT and pulmunary emboli and any embolic events.&#13;
6-recent MI and CVA during last 6 month&#13;
7-known cases of coagulopathy and thrombocytopenia.</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z96.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hip-joint replacement (partial)(total)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In case group after induction of anesthesia we  infuse 30mg/kg fibrinogen concentrtate IV in 15 minutes.before infusion by means of arterial catheter blood sampling perform and check  it for serum level of fibrinogen in both groups( for baseline).during surgery with 30 minute intervals mean atreial pressure would be registered.blood loss is estimated by means of caclculating number of guazes an longuazes and suction container.each guaze and longuaze consist of 20 and 50 ml respectively.maximum allowable blood loss would be calculated by this equationABL=65 X body weightX(patient Hb - desired Hb for sex an age)/optimal Hb.volume of packed RBC contains about 250 ml RBC which would be diluted with 250 ml warm normal saline and transfused for compensation of blood loss.during surgery with warm crystaloids and warm forced air and thermal monitoring maintaining normothermia.monitoring of acid base  would be performed.</i_keyword>
      <i_keyword>In control(placebo) group after induction of anesthesia we  infuse normal saline in equivalent volume of fibrinogen.before infusion by means of arterial catheter blood sampling perform and check  it for serum level of fibrinogen in both groups( for baseline).during surgery with 30 minute intervals mean atreial pressure would be registered.blood loss is estimated by means of caclculating number of guazes an longuazes and suction container.each guaze and longuaze consist of 20 and 50 ml respectively.maximum allowable blood loss would be calculated by this equationABL=65 X body weightX(patient Hb - desired Hb for sex an age)/optimal Hb.volume of packed RBC contains about 250 ml RBC which would be diluted with 250 ml warm normal saline and transfused for compensation of blood loss.during surgery with warm crystaloids and warm forced air and thermal monitoring maintaining normothermia.monitoring of acid base  would be performed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Volume of transfused packed RBC during and after totla hip arthroplasty surgery. Timepoint: any time during and after surgery that needs transfusion. Method of measurement: in mili liter.</prim_outcome>
      <prim_outcome>Volume of bleeding during and after totla hip arthroplasty surgery. Timepoint: during and after surgery. Method of measurement: calculating number of gauzes and longauze and suction fluid in mililiter.</prim_outcome>
      <prim_outcome>Level of hemoglobin during and after surgery. Timepoint: during and 24 hour after surgery. Method of measurement: check of hemoglobin level in perioperative period by CBC test.</prim_outcome>
      <prim_outcome>Complications of transfusion. Timepoint: during and after surgery. Method of measurement: subjective if the patient is awakw and objective if the patient is anesthesized.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Volume of transfused other blood products. Timepoint: during and after surgery. Method of measurement: as mililiter or unit of transfused product.</sec_outcome>
      <sec_outcome>Thromboembolic events. Timepoint: during hospitalisation and after discharge up to 2 weeks(according to fibrinogen half life). Method of measurement: by post operative visit and examination, phone follow up until 2 weeks after discharge.</sec_outcome>
      <sec_outcome>Transfusion related long term complication. Timepoint: long term after surgery. Method of measurement: subjective by patient declarement or complain or objective by take history and physical exam and labratory tests if needed.</sec_outcome>
      <sec_outcome>Cardiovascular complications due to bleeding. Timepoint: during and after surgery. Method of measurement: ECG monitoring and 12 lead ECG trace record during aneshtesia ,history and physical exam after surgery.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Siences- Vice-chancellor for reseach</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-07-28</approval_date>
        <contact_name>committee of ethics in research-Tehran University of Medical Sciences</contact_name>
        <contact_address>keshavarz Blv- edge of qods St-6 th floor -central organisation of TUMS tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-07-28</approval_date>
        <contact_name>TUMS committe of ethics in research</contact_name>
        <contact_address>keshavarz Blv- edge of qods St-central organisation of TUMS tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
